null
SMILES: COC(=O)c1cc2NC(=O)\C(=C(/Nc3ccc(C(=O)NCCN4CCNC(=O)C4)c(F)c3)c3ccccc3)c2cc1C
InChI Key: InChIKey=PTMRLZVVTLYCDK-DQSJHHFOSA-N
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 15.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA, 1 mM DTT and 2 mM MnCl2. The inhibitory activities of compoun... | Citation and Details BindingDB Entry DOI: 10.7270/Q2XP784N | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fibroblast growth factor receptor 3 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 15.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED US Patent | Assay Description The inhibitory activities of compounds of the invention against FGFR3 (FGFR3 Kinase Enzyme System: Promega), were evaluated by mixing the FGFR3 prote... | US Patent US10669235 (2020) BindingDB Entry DOI: 10.7270/Q2XW4NVJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Platelet-derived growth factor receptor alpha (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED US Patent | Assay Description The inhibitory activities of compounds of the invention against PDGFRα (PDGFRα Kinase Enzyme System: Promega), were evaluated by mixing the... | US Patent US10669235 (2020) BindingDB Entry DOI: 10.7270/Q2XW4NVJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Platelet-derived growth factor receptor beta (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED US Patent | Assay Description The inhibitory activities of compounds of the invention against PDGFRβ (PDGFRβ Kinase Enzyme System: Promega), were evaluated by mixing the... | US Patent US10669235 (2020) BindingDB Entry DOI: 10.7270/Q2XW4NVJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Platelet-derived growth factor receptor alpha (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... | Citation and Details BindingDB Entry DOI: 10.7270/Q2XP784N | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Platelet-derived growth factor receptor beta (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 25.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... | Citation and Details BindingDB Entry DOI: 10.7270/Q2XP784N | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 39.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... | Citation and Details BindingDB Entry DOI: 10.7270/Q2XP784N | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor receptor 2 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 39.8 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED US Patent | Assay Description The inhibitory activities of compounds of the invention against VEGFR2 (VEGFR2 Kinase Enzyme System: Promega), were evaluated by mixing the VEGFR2 pr... | US Patent US10669235 (2020) BindingDB Entry DOI: 10.7270/Q2XW4NVJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 79.4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED US Patent | Assay Description The inhibitory activities of compounds of the invention against FGFR1 (FGFR1 Kinase Enzyme System: Promega), were evaluated by mixing the FGFR1 prote... | US Patent US10669235 (2020) BindingDB Entry DOI: 10.7270/Q2XW4NVJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Fibroblast growth factor receptor 1 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 79.4 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA and 1 mM DTT. The inhibitory activities of compounds of the in... | Citation and Details BindingDB Entry DOI: 10.7270/Q2XP784N | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor receptor 1 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 316 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
RESPIVERT LIMITED US Patent | Assay Description The inhibitory activities of compounds of the invention against VEGFR1 (VEGFR1 Kinase Enzyme System: Promega), were evaluated by mixing the VEGFR1 pr... | US Patent US10669235 (2020) BindingDB Entry DOI: 10.7270/Q2XW4NVJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor receptor 1 (Homo sapiens (Human)) | BDBM445264 (US10669235, Example 55 | US11208381, Example 55) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 316 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
TBA | Assay Description Assay was performed in buffer containing 40 mM Tris pH 7.5, 20 mM MgCl2, 0.1 mg/mL BSA, 1 mM DTT and 2 mM MnCl2. The inhibitory activities of compoun... | Citation and Details BindingDB Entry DOI: 10.7270/Q2XP784N | |||||||||||
More data for this Ligand-Target Pair |